Wkly falling wedge setting up for a market structure break and rest to start a 5 wave move possibly. looking for a clearance of the Dec 2, 2019 orderblock for long-term growth
Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The Company...
After the last pump and dump of IGC caused by Cohort 2 of IGC`s Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients now India Globalization Capital comes with another bullish news on the subject: the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer’s trial participants! My first target is the 2.10usd resistance.
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support. The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data...
The FDA is unlikely to approve Ardelyx`s drug for dialysis patients. Ardelyx received a letter from the FDA stating that deficiencies in the information provided had been found that would preclude discussion of approvals Ardelyx has sought. The most likely target is the 1.6usd support line from which it can bounce up.
Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug...
Seeing a Volatility Contraction Pattern (VCP) from the 3 hour time frame with a Parabolic SAR switching below the candles. I'm very bullish on OCGN since during the April 30th overall market bearishness, OCGN holds its place and is the only green candle in my watchlist. Another thing to look is from the weekly time frame which in my technical analysis using the...
Disclaimer: I do own a position and you may want to do your own DD, since this post maybe bias even if its not. Please do your own research. Novan is a pennystock biotech that picked up steam last fall like many pennystocks, but through out 2021 stocks have been getting hit with biotech and pennystocks/low caps being the worst hit sectors. Cathie Woods states in...
Target 1: $29 Target 2: $45 Target 3: $80 If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement. Corium expects to make AZSTARYS commercially available in the U.S. as early as the second...
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Phase I/II Clinical Trial As announced in July 2020, the FDA had requested further manufacturing information, updated safety and efficacy data for all patients dosed, and provided direction on total viral load to be administered per patient. Based on the Company’s response to these requests, the...
On the verge of FDA approval for a new product, multiple analysts recently adjusting price targets to $6 plus. In a market full of mania, a stock with good fundamentals may get overhyped especially about something as legitimate as FDA approval. Who's not talking about SESN and ENZC right now??? If FDA approval falls through both stocks will suffer a lot, so be...
Cup and handle with a range of $2+ (without catalyst) to its catalyst this thing could be a monster in disguise
MYCO has formed a prefect cup & handle on the daily - 4 hits against an important 0.60 resistance - handle dropped perfectly on the 0.5 fib support level - price is currently consolidating right below resistance Fundamentals in the psychedelic space are lining up perfectly for a MYCO breakout. - they are 1 in only 4 companies currently approved for phase 2 FDA...
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also...